Precision Breakthrough: Inavolisib Redefines Survival in PIK3CA-Mutant Breast Cancer

　　Precision Breakthrough:Inavolisib Redefines Treatment for PIK3CA-Mutant Breast Cancer

　　Breast cancer remains the leading cause of cancer death in women globally,with metastatic disease(mBC)carrying a dismal 5-year survival rate of 20%.In the era of precision oncology,PIK3CA mutations(45.6%in Chinese patients)have emerged as a critical target—driving PI3K-AKT-mTOR pathway dysregulation,endocrine resistance,and rapid progression.As China's first approved high-selectivity PI3Kαinhibitor,Inavolisib offers a dual advantage of"deep pathway suppression with minimal toxicity,"opening a new therapeutic paradigm for HR+/HER2-metastatic breast cancer(MBC)with PIK3CA mutations.

　　Breakthrough Evidence:INAVO120 Trial Milestones

　　NMPA approval in March 2025 for Inavolisib+palbociclib+fulvestrant was based on the INAVO120 Phase III trial:

　　PFS extended by 10 months(17.2 vs 7.3 months,HR=0.42)

　　OS improved by 7 months(34.0 vs 27.0 months,HR=0.67)

　　ORR reached 62.7%,with median DoR of 19.2 months

　　Crucially,this regimen preserves quality of life—median time to first chemotherapy extended to 35.6 months,achieving true"efficacy with tolerability."

　　Expanding Horizons:From HR+/HER2-to HER2+

　　The INAVO122 trial is exploring Inavolisib in HER2+PIK3CA-mutant patients.A case of multi-drug-resistant HER2+MBC achieved partial response(PR)within 4 months after ctDNA-guided therapy with Inavolisib+elacestrant+anti-HER2 agents,with PFS exceeding 4 months.This validates Inavolisib’s ability to overcome complex resistance and drives the shift from"single-target"to"multi-pathway synergy"in treatment.

　　Conclusion:The New Era of Precision Oncology

　　Inavolisib’s approval ushers in a molecularly driven era for breast cancer care in China.With gene testing as the foundation and targeted therapy matched to biomarkers,patients gain both extended survival and enhanced quality of life.Future studies(INAVO120/122)aim to expand Inavolisib’s role into earlier lines of therapy,realizing the vision of"precision intervention,lifelong benefit"in breast cancer management.